GlassScriptPhysician profile
William H Davis
NPI 1598229676
$11,642.15
in general payments reported to CMS, 2019-2025
43 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,217 · 2022: $2,421 · 2023: $2,357 · 2024: $2,237 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,934 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,934.28 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,112.61 | 2021-2025 | |
| Pfizer INC. | $1,144.76 | 2021-2025 | |
| Lilly USA, LLC | $994.81 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $928.22 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $692.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $578.43 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.88 | 2021-2025 | Xifaxan, Relistor |
| Amgen INC. | $485.36 | 2021-2025 | Repatha, Otezla, Repatha |
| Preventric Diagnostics, INC. | $374.10 | 2022 | |
| Abbott Laboratories | $369.05 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astellas Pharma US INC | $345.97 | 2021-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $335.05 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $314.12 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $257.05 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $239.48 | 2021-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $165.12 | 2021-2025 | Verquvo, Belsomra, Vaxneuvance |
| Axsome Therapeutics, INC. | $148.92 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $141.07 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Exact Sciences Corporation | $135.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $116.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.19 | 2025 | Caplyta |
| Amarin Pharma, INC. | $109.83 | 2021-2022 | |
| Corium, LLC | $107.05 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $95.11 | 2022 | |
| Mylan Specialty L.P. | $86.77 | 2021-2024 | Yupelri |
| Neos Therapeutics, LP | $86.62 | 2021-2022 | |
| Corcept Therapeutics | $82.23 | 2024-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $69.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $58.56 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $46.07 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.82 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $41.09 | 2024-2025 | Eliquis |
| Eisai INC. | $41.08 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $34.91 | 2024 | Dojolvi |
| Inari Medical, INC. | $34.09 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Jazz Pharmaceuticals INC. | $30.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.94 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $19.32 | 2022 | |
| Viatris Specialty LLC | $17.24 | 2025 | Yupelri |
| Nevro Corp. | $16.82 | 2022 | |
| Hologic Sales and Service, LLC | $15.84 | 2024 | Aptima, Thinprep 2000 Processor |
| Novartis Pharmaceuticals Corporation | $14.80 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.18 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.